Business
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
MILAN, Italy & MORRISTOWN, N.J., March 11, 2025--Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.
About this update from Newron Pharmaceuticals S.p.a.
MILAN, Italy & MORRISTOWN, N.J., March 11, 2025 --( BUSINESS WIRE )-- Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will participate in a fireside chat at the 37 th Annual ROTH Conference on Monday, March 17 at 11:30 a.m. PDT. A live audio webcast of the fireside chat can be accessed on the ROTH Conference website here . About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available first- and second-generation antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: www.newron.com/ View source version on businesswire.com: https://www.businesswire.com/news/home/20250311816061/en/ Contacts For more information, please contact: Newron Stefan Weber – CEO +39 02 6103 46 26 [email protected] UK/Europa Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting +44 20 3727 1000 [email protected] Switzerland Valentin Handschin, IRF +41 43 244 81 54 [email protected] Germany/Europa Anne Hennecke / Maximilian Schur, MC Services +49 211 52925227 [email protected] USA Paul Sagan, LaVoieHealthScience +1 617 374 8800, Ext. 112 [email protected]
View stock analysis, news, and events for Newron Pharmaceuticals S.p.a.